Intercept Pharmaceuticals Future Growth
Future criteria checks 4/6
Intercept Pharmaceuticals is forecast to grow earnings and revenue by 42.4% and 2.3% per annum respectively. EPS is expected to grow by 42.7% per annum. Return on equity is forecast to be 46.4% in 3 years.
Key information
42.4%
Earnings growth rate
42.7%
EPS growth rate
Biotechs earnings growth | 27.3% |
Revenue growth rate | 2.3% |
Future return on equity | 46.4% |
Analyst coverage | Good |
Last updated | 07 Nov 2023 |
Recent future growth updates
Recent updates
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive
Jun 08Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?
Apr 11Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?
Dec 20Intercept touts Ocaliva benefit in transplant-free survival in liver disease type
Sep 20Intercept cuts debt further with deal to exchange convertible notes
Sep 02Intercept reduces debt with repurchases of $327.9M convertible notes
Aug 19Intercept Pharmaceuticals: Too Risky To Buy At This Stage
Aug 13Intercept Pharma Q2 2022 Earnings Preview
Aug 02Intercept to resubmit for FDA approval of NASH candidate after new analysis
Jul 07Intercept: Increase Of Ocaliva Sales And A Few Catalysts
May 23Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
May 10Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH
Mar 05Intercept names Andrew Saik as chief financial officer
Jun 07Intercept Pharmaceuticals slides as FDA restricts Ocaliva use
May 26Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
May 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 362 | 98 | 150 | 177 | 13 |
12/31/2024 | 362 | 107 | 125 | 147 | 15 |
12/31/2023 | 331 | -34 | -15 | -51 | 4 |
9/30/2023 | 318 | -57 | -63 | -63 | N/A |
6/30/2023 | 306 | -159 | -96 | -96 | N/A |
3/31/2023 | 295 | -173 | -59 | -58 | N/A |
12/31/2022 | 286 | -175 | -27 | -27 | N/A |
9/30/2022 | 277 | -202 | -18 | -17 | N/A |
6/30/2022 | 266 | -115 | 3 | 3 | N/A |
3/31/2022 | 263 | -120 | -7 | -7 | N/A |
12/31/2021 | 261 | -136 | -41 | -41 | N/A |
9/30/2021 | 275 | -144 | -65 | -62 | N/A |
6/30/2021 | 288 | -193 | -110 | -106 | N/A |
3/31/2021 | 297 | -231 | -130 | -126 | N/A |
12/31/2020 | 234 | -273 | -176 | -172 | N/A |
9/30/2020 | 301 | -321 | -217 | -215 | N/A |
6/30/2020 | 283 | -339 | -222 | -221 | N/A |
3/31/2020 | 272 | -347 | -253 | -252 | N/A |
12/31/2019 | 252 | -345 | -238 | -237 | N/A |
9/30/2019 | 234 | -335 | -230 | -229 | N/A |
6/30/2019 | 219 | -314 | -235 | -234 | N/A |
3/31/2019 | 196 | -318 | -236 | -235 | N/A |
12/31/2018 | 180 | -309 | -241 | -241 | N/A |
9/30/2018 | 164 | -333 | -265 | -264 | N/A |
6/30/2018 | 159 | -341 | -271 | -269 | N/A |
3/31/2018 | 146 | -352 | -283 | -277 | N/A |
12/31/2017 | 131 | -360 | -276 | -265 | N/A |
9/30/2017 | 107 | -369 | -290 | -278 | N/A |
6/30/2017 | 71 | -385 | N/A | -334 | N/A |
3/31/2017 | 46 | -376 | N/A | -350 | N/A |
12/31/2016 | 25 | -413 | N/A | -342 | N/A |
9/30/2016 | 12 | -381 | N/A | -319 | N/A |
6/30/2016 | 7 | -343 | N/A | -240 | N/A |
3/31/2016 | 2 | -314 | N/A | -203 | N/A |
12/31/2015 | 3 | -226 | N/A | -163 | N/A |
9/30/2015 | 3 | -173 | N/A | -129 | N/A |
6/30/2015 | 3 | -158 | N/A | -120 | N/A |
3/31/2015 | 3 | -77 | N/A | -105 | N/A |
12/31/2014 | 2 | -283 | N/A | -88 | N/A |
9/30/2014 | 2 | -261 | N/A | -66 | N/A |
6/30/2014 | 2 | -257 | N/A | -49 | N/A |
3/31/2014 | 2 | -304 | N/A | -35 | N/A |
12/31/2013 | 2 | -68 | N/A | -28 | N/A |
9/30/2013 | 2 | -86 | N/A | -22 | N/A |
6/30/2013 | 2 | -61 | N/A | -19 | N/A |
3/31/2013 | 2 | -53 | N/A | -17 | N/A |
12/31/2012 | 2 | -46 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: ICPT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ICPT is expected to become profitable in the next 3 years.
Revenue vs Market: ICPT's revenue (2.3% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: ICPT's revenue (2.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICPT's Return on Equity is forecast to be very high in 3 years time (46.4%).